Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Respironics, Inc.
Philips’ revenues contraction in the first quarter of 2022 was less than feared and its order book remains impressive, but challenges presented by the recall program and generic post-COVID factors for the year ahead remain substantial.
Frans van Houten has promised a summer update on Royal Philips’ medium-term outlook after the company was hit from all sides in late 2021. He expects the resulting headwinds to persist into early 2022.
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
Post-Pandemic World: Former VA Secretary Predicts Acceleration In Telemedicine, Digitalization, Hospital Redesign
Former VA Secretary David Shulkin said health care post-COVID-19 requires a makeover with greater hospital integration and ongoing telemedicine to address behavioral and physical issues.
- Other Names / Subsidiaries